Patents Assigned to Kowa Co., Ltd.
-
Publication number: 20230321051Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (1 is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: May 24, 2023Publication date: October 12, 2023Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20230019803Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: September 2, 2022Publication date: January 19, 2023Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20220047585Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.Type: ApplicationFiled: November 1, 2021Publication date: February 17, 2022Applicant: KOWA CO., LTD.Inventors: Shin SUGIMOTO, Ken MIZUNO, Masatoshi TAKAHASHI, Makoto KANEBAKO
-
Publication number: 20210205274Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: February 26, 2021Publication date: July 8, 2021Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20210052599Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.Type: ApplicationFiled: November 10, 2020Publication date: February 25, 2021Applicant: KOWA CO., LTD.Inventor: Ken MIZUNO
-
Publication number: 20200246315Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate the compound or the salt.Type: ApplicationFiled: April 22, 2020Publication date: August 6, 2020Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro Murakami
-
Patent number: 10568860Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.Type: GrantFiled: August 30, 2007Date of Patent: February 25, 2020Assignees: KOWA CO., LTD., SENTANIRYOUKAIHATSU CO., LTD.Inventor: Kensuke Egashira
-
Publication number: 20200030340Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.Type: ApplicationFiled: September 4, 2019Publication date: January 30, 2020Applicant: KOWA CO., LTD.Inventor: Ken MIZUNO
-
Publication number: 20200030299Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: October 2, 2019Publication date: January 30, 2020Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20190328730Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.Type: ApplicationFiled: July 8, 2019Publication date: October 31, 2019Applicant: KOWA CO., LTD.Inventors: Shin SUGIMOTO, Ken MIZUNO, Masatoshi TAKAHASHI, Makoto KANEBAKO
-
Patent number: 10335306Abstract: A supporter includes a body section having a back-contact section, a first auxiliary band section of which one end is fixed to the top end of a left side of the back-contact section and the other end is fixed to the bottom end of a right side of the back-contact section, a second auxiliary band section forming a pair with the first auxiliary band section, a first ring arranged to slide between the one end and the other end of the first auxiliary band section, a second ring forming a pair with the first ring, a first adjustment band section of which one end is fixed to loops on a right end side of the body section and the other end can be fastened to loops on the right end side of the body section, and a second adjustment band section forming a pair with the first adjustment band section.Type: GrantFiled: June 6, 2014Date of Patent: July 2, 2019Assignees: KOWA CO., LTD, ADVANCING INC., DMCHAIN COOPERATIVEInventors: Hidetaka Okada, Hitoshi Ojima, Hidenori Kaseno
-
Publication number: 20190167644Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2 which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: February 7, 2019Publication date: June 6, 2019Applicant: Kowa Co. Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20180185384Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.Type: ApplicationFiled: February 27, 2018Publication date: July 5, 2018Applicant: KOWA CO., LTD.Inventor: Ken MIZUNO
-
Publication number: 20180078530Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: October 18, 2017Publication date: March 22, 2018Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro MURAKAMI
-
Publication number: 20170020889Abstract: There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma.Type: ApplicationFiled: October 4, 2016Publication date: January 26, 2017Applicant: KOWA CO., LTD.Inventor: Ken MIZUNO
-
Patent number: 9540344Abstract: The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.Type: GrantFiled: December 5, 2014Date of Patent: January 10, 2017Assignee: KOWA CO., LTD.Inventors: Noriaki Gomi, Tadaaki Ohgiya, Kimiyuki Shibuya
-
Patent number: 9526651Abstract: A lower leg supporter supports a gastrocnemius muscle from upper, lower, left, and right sides without interfering with movement of an Achilles tendon and which can suppress excessive vibration or deformation of such muscle to reduce a wearer's fatigue. The lower leg supporter includes a first anchor section that secures a tubular knitted fabric to a below-knee part, a second anchor section that secures the tubular knitted fabric to an above-ankle part, and an X-shaped gastrocnemius muscle support section located at a joining part of such muscle and an Achilles tendon on the back surface side of the tubular knitted fabric. Two ends of the X-shaped knitted fabric are joined to the first anchor section to support the gastrocnemius muscle. The other two ends of the X-shaped knitted fabric are joined to the second anchor section, and extend to both edges of the Achilles tendon.Type: GrantFiled: December 28, 2011Date of Patent: December 27, 2016Assignee: KOWA CO., LTD.Inventors: Yoshihiko Kozasa, Hidefumi Koga
-
Publication number: 20160243086Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.Type: ApplicationFiled: May 3, 2016Publication date: August 25, 2016Applicant: Kowa Co., Ltd.Inventors: Toshiaki TAKIZAWA, Kentaro Murakami
-
Publication number: 20150320748Abstract: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvaType: ApplicationFiled: July 9, 2015Publication date: November 12, 2015Applicant: KOWA CO., LTD.Inventors: Kimiyuki SHIBUYA, Tadaaki Ohgiya, Takeshi Murakami
-
Publication number: 20150306098Abstract: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvaType: ApplicationFiled: July 9, 2015Publication date: October 29, 2015Applicant: Kowa Co., Ltd.Inventors: Kimiyuki SHIBUYA, Tadaaki Ohgiya, Takeshi Murakami